Literature DB >> 20383517

The European strategy on low dose risk research and the role of radiation quality according to the recommendations of the "ad hoc" High Level and Expert Group (HLEG).

Mauro Belli1, Andrea Ottolenghi, Wolfgang Weiss.   

Abstract

Health effects of exposures at low doses and/or low dose rates are recognized as requiring intensive research activity to answer several questions. To address these issues at a strategic level in Europe, with the perspective of integrating national and EC efforts (in particular those within the Euratom research programmes), a "European High Level and Expert Group (HLEG) on low dose risk research" was formed and carried out its work during 2008. The Group produced a report published by the European Commission in 2009 and available on the website http://www.hleg.de . The more important research issues identified by the HLEG were as follows: (a) the shape of dose-response for cancer; (b) the tissue sensitivities for cancer induction; (c) the individual variability in cancer risk; (d) the effects of radiation quality (type); (e) the risks from internal radiation exposure; and (f) the risks of, and dose response relationships for, non-cancer diseases. In this paper, the radiation quality issues are especially considered, since they are closely linked to health problems and related radioprotection in space and in emerging radiotherapeutic techniques (i.e., hadrontherapy). The peculiar features of low-fluence, high-LET radiation exposures can question in particular the validity of the radiation-weighting factor (w ( R )) approach. Specific strategies are therefore needed to assess such risks. A multi-scale/systems biology approach, based on mechanistic studies coordinated with molecular-epidemiological studies, is considered essential to elucidate differences and similarities between specific effects of low- and high-LET radiation.

Entities:  

Mesh:

Year:  2010        PMID: 20383517     DOI: 10.1007/s00411-010-0284-2

Source DB:  PubMed          Journal:  Radiat Environ Biophys        ISSN: 0301-634X            Impact factor:   1.925


  5 in total

1.  M-FISH analysis shows that complex chromosome aberrations induced by alpha -particle tracks are cumulative products of localized rearrangements.

Authors:  Rhona M Anderson; David L Stevens; Dudley T Goodhead
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-30       Impact factor: 11.205

Review 2.  Radiobiological problems in space. An overview.

Authors:  W Schimmerling
Journal:  Radiat Environ Biophys       Date:  1992       Impact factor: 1.925

3.  Dose and dose rate effectiveness of space radiation.

Authors:  W Schimmerling; F A Cucinotta
Journal:  Radiat Prot Dosimetry       Date:  2006-12-14       Impact factor: 0.972

Review 4.  Heavy ion carcinogenesis and human space exploration.

Authors:  Marco Durante; Francis A Cucinotta
Journal:  Nat Rev Cancer       Date:  2008-05-02       Impact factor: 60.716

5.  Immunofluorescence detection of clustered gamma-H2AX foci induced by HZE-particle radiation.

Authors:  N Desai; E Davis; P O'Neill; M Durante; F A Cucinotta; H Wu
Journal:  Radiat Res       Date:  2005-10       Impact factor: 2.841

  5 in total
  3 in total

1.  Space radiation research in Europe: flight experiments and ground-based studies.

Authors:  M Durante; G Reitz; O Angerer
Journal:  Radiat Environ Biophys       Date:  2010-06-08       Impact factor: 1.925

Review 2.  Multidisciplinary European Low Dose Initiative (MELODI): strategic research agenda for low dose radiation risk research.

Authors:  M Kreuzer; A Auvinen; E Cardis; M Durante; M Harms-Ringdahl; J R Jourdain; B G Madas; A Ottolenghi; S Pazzaglia; K M Prise; R Quintens; L Sabatier; S Bouffler
Journal:  Radiat Environ Biophys       Date:  2017-12-15       Impact factor: 1.925

3.  The origin of neutron biological effectiveness as a function of energy.

Authors:  G Baiocco; S Barbieri; G Babini; J Morini; D Alloni; W Friedland; P Kundrát; E Schmitt; M Puchalska; L Sihver; A Ottolenghi
Journal:  Sci Rep       Date:  2016-09-22       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.